- Home
- ACIU vs BHR Comparison
ACIU vs BHR Comparison
Compare ACIU & BHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- BHR
- Stock Information
- Founded
- ACIU 2003
- BHR 2013
- Country
- ACIU Switzerland
- BHR United States
- Employees
- ACIU N/A
- BHR N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- BHR Real Estate Investment Trusts
- Sector
- ACIU Health Care
- BHR Real Estate
- Exchange
- ACIU Nasdaq
- BHR Nasdaq
- Market Cap
- ACIU 189.1M
- BHR 171.6M
- IPO Year
- ACIU 2016
- BHR N/A
- Fundamental
- Price
- ACIU $2.07
- BHR $2.44
- Analyst Decision
- ACIU Strong Buy
- BHR
- Analyst Count
- ACIU 1
- BHR 0
- Target Price
- ACIU $12.00
- BHR N/A
- AVG Volume (30 Days)
- ACIU 125.1K
- BHR 250.6K
- Earning Date
- ACIU 08-05-2025
- BHR 07-31-2025
- Dividend Yield
- ACIU N/A
- BHR 8.10%
- EPS Growth
- ACIU N/A
- BHR N/A
- EPS
- ACIU N/A
- BHR N/A
- Revenue
- ACIU $32,014,254.00
- BHR $723,586,000.00
- Revenue This Year
- ACIU N/A
- BHR N/A
- Revenue Next Year
- ACIU $533.21
- BHR $2.32
- P/E Ratio
- ACIU N/A
- BHR N/A
- Revenue Growth
- ACIU 91.20
- BHR N/A
- 52 Week Low
- ACIU $1.43
- BHR $1.80
- 52 Week High
- ACIU $4.26
- BHR $3.95
- Technical
- Relative Strength Index (RSI)
- ACIU 55.57
- BHR 48.65
- Support Level
- ACIU $2.00
- BHR $2.47
- Resistance Level
- ACIU $2.15
- BHR $2.59
- Average True Range (ATR)
- ACIU 0.13
- BHR 0.09
- MACD
- ACIU -0.01
- BHR -0.02
- Stochastic Oscillator
- ACIU 80.92
- BHR 12.00
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About BHR Braemar Hotels & Resorts Inc.
Braemar Hotels & Resorts Inc is a real estate investment trust company that invests in high revenue per available room, or RevPAR, luxury, upper-upscale and upscale hotels in gateway and resort locations. The firm operates in various U.S. states such as California, Texas, Washington, Philadelphia, Florida, and Illinois as well as Washington, D.C. and St. Thomas, U.S. Virgin Islands. The company operates through its direct hotel investment segment of the hotel lodging industry. Its revenue streams include rooms, food and beverage, and other. The firm's hotels operate under various brands, such as Marriott, Hilton, Courtyard, and, among others.